

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Manko Joseph M. Jr.		2. Issuer Name and Ticker or Trading Symbol KORU Medical Systems, Inc. [KRMD]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
1717 ARCH STREET, 39TH FLOOR		3. Date of Earliest Transaction (Month/Day/Year) 06/30/2022		<input checked="" type="checkbox"/> Director Officer (give title below) <input checked="" type="checkbox"/> 10% Owner Other (specify below)	
PHILADELPHIA, PA 19103		4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/30/2022		A		6,002	A	\$ 0 (1)	7,419,649	I	By Horton Capital Partners Fund, LP (2)
Common Stock								3,067,369	I	By Horton Freedom, L.P. (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Manko Joseph M. Jr. 1717 ARCH STREET 39TH FLOOR PHILADELPHIA, PA 19103	X	X		
Horton Capital Management, LLC 1717 ARCH STREET 39TH FLOOR PHILADELPHIA, PA 19103		X		
Horton Capital Partners, LLC 1717 ARCH STREET 39TH FLOOR PHILADELPHIA, PA 19103		X		
Horton Capital Partners Fund, L.P. 1717 ARCH STREET 39TH FLOOR PHILADELPHIA, PA 19103		X		
Horton Freedom, L.P. 1717 ARCH STREET 39TH FLOOR PHILADELPHIA, PA 19103				Less than 10% Owner

Signatures

/s/ Joseph M. Manko, Jr.		07/05/2022
	Signature of Reporting Person	Date
/s/ Joseph M. Manko, Jr., Managing Member of Horton Capital Management, LLC		07/05/2022
	Signature of Reporting Person	Date
/s/ Joseph M. Manko, Jr., Managing Member of Horton Capital Partners, LLC		07/05/2022
	Signature of Reporting Person	Date
/s/ Joseph M. Manko, Jr., Managing Member of Horton Capital Partners, LLC, the General Partner of Horton Capital Partners Fund, LP		07/05/2022
	Signature of Reporting Person	Date
/s/ Joseph M. Manko, Jr., Managing Member of Horton Capital Partners, LLC, the General Partner of Horton Freedom, L.P.		07/05/2022
	Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) See Exhibit 99.1 to this Form 4 for explanation of note (1).

(2) See Exhibit 99.1 to this Form 4 for explanation of note (2).

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any ex

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

EXHIBIT 99.1 TO FORM 4

Explanation of Responses:

- (1) On June 30, 2022, Horton Capital Partners Fund, LP, a Delaware limited partnership (“HCPF”), was granted 6,002 shares of Repro Med Systems, Inc. (the “Issuer”) common stock (“Common Stock”) in consideration for Mr. Manko’s service as a Director of the Issuer for the quarter ended June 30, 2022.
- (2) This Form 4 is filed jointly by Horton Capital Management, LLC, a Delaware limited liability company (“HCM”), Horton Capital Partners LLC, a Delaware limited liability company (“HCP”), HCPF, and Joseph M. Manko, Jr. Pursuant to investment advisory agreements, HCM maintains investment and voting power with respect to shares of Common Stock of the Issuer held by HCPF and Horton Freedom, L.P., a Delaware limited partnership (“Horton Freedom”). However, despite the delegation of investment and voting power to HCM, HCP may be deemed to be the beneficial owner of such Common Stock because, in the event HCM’s investment advisory agreement with respect to such Common Stock is terminated, HCP has the right to assume HCM’s discretionary investment and voting authority with respect to such Common Stock. HCP is the general partner of HCPF and Horton Freedom. Mr. Manko is the managing member of both HCM and HCP. As a result of the transaction disclosed herein, HCM no longer has discretionary investment nor voting authority with respect to such shares of Common Stock.

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.
